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Abstract Reactive astrogliosis is a cellular manifestation of
neuroinflammation and occurs in response to all forms and
severities of the central nervous system (CNS)’s injury and
disease. Both astroglial proliferation and antiapoptotic pro-
cesses are aspects of astrogliosis. However, the underlying
mechanism of this response remains poorly understood. In
addition, little is known about why activated astrocytes are
more resistant to stress and inflammation. CCAAT/enhancer
binding protein delta (CEBPD) is a transcription factor found
in activated astrocytes that surround β-amyloid plaques. In
this study, we found that astrocytes activation was attenuated
in the cortex and hippocampus of APPswe/PS1 E9 (AppTg)/
Cebpd−/−mice. Furthermore, an increase in apoptotic astro-
cytes was observed in AppTg/Cebpd−/−mice, suggesting that
CEBPD plays a functional role in enhancing the antiapoptotic
ability of astrocytes. We found that Zinc Finger Protein 179
(ZNF179) was a CEBPD-regulated gene that played an
antiapoptotic, but not proliferative, role in astrocytes.
The transcriptions of the proapoptotic genes, insulin-
like growth factor binding protein 3 (IGFBP3) and
BCL2-interacting killer (BIK), were suppressed by
ZNF179 via its interaction with the promyelocytic leu-
kemia zinc finger (PLZF) protein in astrocytes. This
study provides the first evidence that ZNF179, PLZF,
IGFBP3, and BIK contributed to the novel CEBPD-
induced antiapoptotic feature of astrocytes.
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Introduction
Aging is accompanied by a low-grade chronic neuroinflam-
mation and aged rat neurons show signs of programmed cell
death [1, 2]. Astrocyte is the most abundant cell type of glial
cells and suggests being involved in the induction of neuro-
inflammation. Previous studies reported no change in the
number of astrocytes in the hippocampus of male aged mice
[2] and activated astrocytes are more resistant to death signals
in highly inflammatory environments [3, 4]. Interestingly, the
number of astrocytes increases by approximately 20 % in
aging brains [5], suggesting that reactive gliosis responds to
injured or damaged neurons during aging. The above discov-
eries indicated that the antiapoptosis of aged astrocytes con-
tributes to the death of neurons. However, the underlying
mechanisms have not been investigated. Alzheimer’s disease
(AD) is pathologically characterized by the age-dependent
deposition of β-amyloid (Aβ) in senile plaques and is associ-
ated with neuroinflammation. Aβ can activate astrocytes,
thus promoting inflammatory cytokines production, which
is believed to modulate the development and/or progres-
sion of AD. Astrogliosis (also known as astrocytosis or
reactive astrocytes) is characterized by the proliferation
and hypertrophy of astrocytes, and is usually observed in
neurodegenerative disorders and central nervous system
(CNS) injuries [6].
CCAAT/enhancer binding protein delta (CEBPD) is a
member of the CCAAT/enhancer binding protein (C/EBP)
family and has been shown to be activated in many inflam-
matory diseases, including AD [7, 8] and rheumatoid arthritis
[9]. CEBPD is responsive to tumor necrosis factor alpha
(TNFα), interleukin-1 beta (IL-1β), interleukin 6 (IL-6), lipo-
polysaccharide, and interferon gamma [8, 10]. In astrocytes,
CEBPD activation attenuates macrophage-mediated phagocy-
tosis of damaged neurons and promotes chemoattraction and
migration of microglia/macrophages through PTX3 andMCP-
1, respectively [8, 11]. However, the function of CEBPD in
astrocytes and neuroinflammation-related diseases, especially
its potential role in astrogliosis, remains largely uninvestigated.
Zinc finger protein 179 (ZNF179 or RNF112) belongs to
the RING finger protein family, which is characterized by a
zinc binding domain that serves as a potent protein binding
interface. Mouse ZNF179 (Znf179) is specifically expressed
in the mouse brain [12, 13]. Znf179 is expressed exclusively
in the mouse brain and the expression is high in MAP2-
positive cells and moderate in glial fibrillary acidic protein
(GFAP)-positive cells in normal subjects [14]. However, the
ZNF179 biology in brain remains largely unclear. A recent
study showed that Znf179 regulates cell cycle exit, which is
critical for neuronal differentiation and plays a potent role in
cell survival [12].
Herein, we found that the loss of GFAP signal associated
with the increase of caspase 3 signal was observed in AppTg/
Cebpd−/− mice. Focusing on the survival (or resistance to
stress-induced apoptosis) of astrocytes in inflammatory envi-
ronment, we first showed that CEBPD played a functional role
in inducing the resistance of cell death in an inflammatory
environment. ZNF179 is attenuated following the IL-1β stim-
ulation in neuronal cells. We further found that ZNF179 is
responsive to CEBPD induction in astrocytes and contributes
the CEBPD-induced antiapoptosis. Two pro-apoptotic genes
insulin-like growth factor binding protein 3 (IGFBP3) and
BCL2-interacting killer (BIK) were identified by a system
approach and were negatively regulated by the complex of
ZNF179 and promyelocytic leukemia zinc finger (PLZF).
These discoveries provide a new insight into the resistance
of astrocytes to inflammation and the control of astrogliosis.
Materials and Methods
Materials
The CEBPD and green fluorescent protein (GFP) antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The GFAP antibody was purchased from
Invitrogen (Carlsbad, CA, USA). The caspase 3 antibody
was purchased from Cell Signaling Technology (Danvers,
MA, USA). The ZNF179 antibody used for immunofluores-
cence was purchased from GeneTex (Irvine, CA, USA), and
the ZNF179 antibody used in the Western blot and immuno-
precipitation assays was obtained from Dr. Yi-Chao Lee. The
TRIzol RNA extraction reagent, Dulbecco’s modified Eagle’s
medium (DMEM), and SuperScript™ III were purchased
from Invitrogen (Carlsbad, CA, USA). All oligonucleotides
were synthesized by MDBio Inc. (Taipei, Taiwan). Fetal bo-
vine serum (FBS) was purchased from HyClone Laboratories
(Logan, UT, USA).
Animals
The APPswe/PS1/E9 bigenic (AppTg) mice were obtained
from the Jackson Laboratory (stock no. 004462, Bar Harbor,
ME, USA). The AppTg mice were crossed with Cebpd-defi-
cient mice (Cebpd−/−), a kind gift from Dr. E. Sterneck [15],
on the C57BL/6 genetic background. Female mice heterozy-
gous for AppTg mice was intercrossed with Cebpd−/− homo-
zygous mice; the offspring (AppTg+/−/Cebpd+/−) were then
bred to each other to produce the AppTg/Cebpd−/− mice in
this study.
Cell Culture and Isolation of Primary Mouse Astrocytes
Human U373MG cells, an established cell line derived from
human astrocytoma and HeLa cells (human cervical
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epithelioid carcinoma cell line), were cultured in DMEM. SH-
SY5Y cells (human neuroblastoma cell line) were maintained
in DMEM/F12. All media contained 10 % FBS, 100 μg/mL
streptomycin, and 100 units/ml penicillin. U373MG cell lines
stably expressing hemagglutinin (HA), HA-ZNF179, or HA-
CEBPD were selected and maintained by regular media con-
taining G418. The primary mouse brain astrocytes were iso-
lated from Cebpd+/+ or Cebpd−/− mice using mechanical dis-
sociation of the brain cortex from newborn pups. The isolated
cells were then filtered through a 70-μm nylon strainer and
cultured in the previously described medium [16] with the
addition of poly-L-lysine (Invitrogen, Carlsbad, CA, USA).
Cell Survival, Proliferation, and Fluorescence-Activated Cell
Sorting Analysis
For the cell survival assay, cells were plated and cultured in the
aforementioned regularmedium for 16 h. The experimental cells
were then treated with or without 100 μg/mL methanesulfonate
(MMS; Sigma, St. Louis, MO, USA) or 5 ng/mL IL-1β
(Invitrogen, Carlsbad, CA, USA). Next, the media was removed
and replaced with diluted 3-(4,5-cimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) reagent for 4 h. The
samples were then measured spectrophotometrically at 595 nm
using an ELISA plate reader. For cell proliferation assay, daily
cell culture samples were counted in a Neubauer chamber after
trypsinization. Viability was assessed by Trypan blue exclusion.
Assays were performed in triplicates. For the apoptosis assay,
cells were plated and cultured in the aforementioned regular
medium for 16 h. The experimental cells were then treated with
or without MMS or IL-1β for 24 h. As indicated times or
experimental conditions, the cells were fixed in cold 70 %
ethanol at −20 °C overnight and then suspended in phosphate-
buffered saline (PBS) containing 0.2%TritonX-100, 0.1mg/ml
RNase and 40 μg/mL propidium iodide at room temperature for
1 h. The apoptosis of experimental cells was analyzed using
flow cytometry (FACSCalibur; BD Biosciences, Mountain
View, CA).
Reverse Transcription-PCR and Quantitative PCR
Total RNA was extracted using the TRIsure RNA extraction
reagent. The synthesis of complementary DNA (cDNA) was
completed with an reverse transcription (RT) reaction using
SuperScript III. Quantitative PCR (Q-PCR) was conducted
using KAPA SYBR FAST qPCR Master Mix (Life
Technologies Corporation and Kapa Biosystems Inc.). PCR
was conducted using a CFX connect real-time PCR system
(Bio-Rad) with the following pairs of specific primers: primer
sequences human CEBPD (S): 5-′GCCATGTACGACGACG
AGAG-3′ and CEBPD (AS): 5-′TGTGATTGCTGTTGAA
GAGGTC-3′; mouse Cebpd (S): 5-′CTCCCGCACACAAC
ATACTG -3′ and Cebpd (AS): 5-′AGTCATGCTTTCCCGT
GTTC-3′, ZNF179 (S): 5-′GAGCAGGGAAACAAGGAT
CA-3′ and ZNF179 (AS): 5-′GGTGGGATGAGTCACGAT
CA-3′, RYBP (S): 5-′TGACATTGCAGTGGTGGTTT-3′ and
RYBP (AS): 5-′CCATGTCAGGACTGGATGTG-3′, BIK
(S): 5-′CCTGGACCCTATGGAGGACT-3′ and BIK (AS):
5-′GGTGAAACCGTCCATGAAAC-3′, GADD45B (S): 5-′
ACCTGCATTGTCTCCTGGTC-3′ and GADD45B (AS): 5-′
TTTGTTTGTGGCAGCAACTC-3′, IGFBP3 (S): 5-′AGGG
CACTCTGGGAACCTAT-3′ and IGFBP3 (AS): 5-′TGCA
GTCATCCGAAGAATTG′.
Western Blot Analysis
Cells were harvested and lysed with modified
radioimmunoprecipitation assay (RIPA) buffer [50 mM
Tris–HCl (pH 7.4), 150 mM sodium chloride, 1 mM
ethylenediamine tetraacetic acid, 1 % NP40, 0.25 %
sodium deoxycholate, 1 mM dithiothreitol, 10 mM NaF,
1 mM PMSF, 1 μg/mL aprotinin, and 1 μg/mL leupeptin].
Lysates were resolved on a sodium dodecyl sulfate-
containing 10 % polyacrylamide gel, then transferred to
a polyvinylidene difluoride nylon membrane and probed
with primary antibodies for target proteins at 4 °C over-
night. The specific proteins were detected by peroxidase-
conjugated secondary antibody incubated at room tempe-
rature for 1 h. The signals were revealed by an enhanced
chemiluminescence Western blot system from Pierce
(Rockford, IL, USA).
Luciferase Reporter Assay
The 5′ flanking regions of ZNF179, IGFBP3 and BIK genes
were obtained by PCR with U373MG genomic DNA and then
individually cloned into a pGL3 basic vector. The primers for the




TGCTACACTAACCAGTGGTC-3′, IGFBP3 (AS): 5′-
HindIII-CCCAAGCTTGGGAATCCAGGCAGGAAGCGG
CTGATC-3′, BIK(S):5′-NheI-CTAGCTAGCTAGCTCTTCCT
CCTTTTGATCAGC-3′, and BIK (AS):5′-BglII-GAAGATCT
TCTAAAACCTGGGCACGGCTC-3′. For the reporter assay,
cells were transfected with the reporters and expression
vectors as indicted using polyJet (SignaGen, Ijamsville,
MD). The lysates of transfected cells were harvested fol-
lowing the manufacturer’s instructions for the luciferase
assay.
Co-Immunoprecipitation Assay
The lysates of U373MG cells were prepared using an immu-
noprecipitation lysis buffer [50 mM NaCl, 0.5 % NP-40,
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10 mM Tris–HCl, (pH 8.0)]. The supernatant was collected
and incubated with anti-GFP antibody at 4 °C for at least 4 h.
Protein-A/G agarose beads were added to the lysates
and the mixtures were incubated and rotated at 4 °C
for 1 h. The beads were collected using centrifugation
and washed three times with modified RIPA buffer. The
proteins bound to the beads were eluted by adding 2X
electrophoresis sample buffer and then subjected to
Western blot analysis.
Lentiviral Short Hairpin RNA Knockdown
The virus was produced from Phoenix cells using a co-
transfection of the various short hairpin RNA (shRNA) ex-
pression vectors in combination with pMD2.G and psPAX2
expression vectors. The expression vectors were obtained
from the National RNAi Core Facility located at the
Genomic Research Center of Institute of Molecular Biology,
Academia Sinica, Taiwan. After determining the viral infec-
tion efficiency, the lentivirus containing shβ-galactosidase
(shLacZ), shCEBPD, or shZNF179 were used to infect
U373MG cells for 48 h. The shRNA sequences in the








Briefly, U373MG cells were treated with 1 % formaldehyde
for 15 min. The cross-linked chromatin was then prepared and
sonicated to an average size of 500 bp. The DNA fragments
were immunoprecipitated with specific antibodies recogniz-
ing CEBPD, ZNF179, PLZF, or control rabbit immunoglob-
ulin G (IgG) at 4 °C for 12–16 h. After reversal of the cross-
linking between proteins and genomic DNA, the precipitated
DNA was amplified by PCR with primers related to the
specific regions on the genomic loci of target genes. The
primers included ZNF179-I forward, 5′-GGGCTCTGTACA
TAGTAGGTACTC-3′ and ZNF179-I reverse, 5′-GCCTCT
ACTGGGCCAGCTGAGGTC-3′ or ZNF179-II forward, 5′-
CTTGGTGCACCCATCTTTGCATC-3′ and ZNF179-II re-
verse, 5 ′-AGGCATTGCTATGATCTGGGTGAG-3 ′ .
IGFBP3 forward, 5′-CACGTGAGAGTCTTCTTGCGTT
GAG-3′ and IGFBP3 reverse, 5′-ATACAGCGCTCCGCAT
TCGTGTG-3′, or BIK forward, 5′-CCCCTGGCTTCGGG
TATGGATCAC-3′ and BIK reverse, 5′-TATCGGGGGGAT
CGATCCATTGAC-3′.
Immunofluorescence Analysis
The frozenmale mouse brain sections (~15–16months of age)
were treated with protein blocker/antibody diluents (Bio SB,
Santa Barbara, CA, USA) for 1 h. In the same buffer solution,
the sections were incubated overnight with primary antibodies
at 4 °C. These primary antibodies included cleaved caspase 3,
GFAP, Aβ, Znf179, and CEBPD. Statistical analysis of im-
munofluorescent staining intensity in cortex or hippocampus
of brain slices from AppTg or AppTg/Cebpd−/−mice was done
using TissueQuest 4.0 image software. For the staining of cell
cultures, U373MG cells were post-fixed in 4 % paraformal-
dehyde in PBS for 20min, followed by 70%methanol in PBS
at −20 °C for 10 min. The fixed U373MG cells were further
incubated with primary antibodies against target proteins in
3 % BSA at 4 °C. Pretreated slides of the tissue sections or
U373MG cells were washed with 0.2 % Triton X-100 in PBS
and then incubated with Alexa 488- or 555-conjugated sec-
ondary antibodies for 1 h at room temperature then washed
again with 0.2 % Triton X-100 in PBS. Next, the glass slides
were counter-stained and mounted with ProLong Gold
antifade reagent with 4′,6-diamidino-2-phenylindole for im-
munofluorescence microscopy.
Statistical Analysis
All experiments were repeated at least three times, and data
were analyzed for statistical significance by two-tailed un-
paired Student’s t test using Prism 5 software. The data were
expressed as means±SEM. Differences were considered sta-
tistically significant when indicated by asterisks.
Results
Astrocyte Activation is Attenuated in the Area Surrounding
β-Amyloid Plaques in AppTg/Cebpd−/− Mice
Activated astrocytes are largely resistant to cell death in a
neuroinflammatory environment. In AD patients and AppTg
mice, the expression of CEBPD and mouse CEBPD (Cebpd),
respectively, is elevated and localized within astrocytes [7, 8]
(Fig. S1A). The immunoreactivity for GFAP, a specific astro-
cyte marker, was attenuated in both the cortex and hippocam-
pus of AppTg/Cebpd−/− mice when compared with AppTg
mice (Fig. 1a, b). To assess whether apoptosis contributes to
the reduction of astrocytes in AppTg/Cebpd−/−mice, activated
caspase 3, an apoptosis marker, was used to measure the death
of astrocytes in brain sections from AppTg and AppTg/
Cebpd−/− mice. As shown in Fig. 1c, d, activated caspase 3
was upregulated and colocalized with the GFAP-positive as-
trocytes in AppTg/Cebpd−/− mice. This suggests that CEBPD
contributes to the survival of astrocytes in AppTg mice.
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CEBPD Plays an Antiapoptotic Role in Astrocytes
Several reports have suggested that astrocytes are more resis-
tant to death in an inflammatory environment when compared
to neurons [3, 17, 18]. CEBPD is known to be activated in
astrocytes in response to IL-1β and TNFα [8, 11]. We first
tested whether the activated CEBPD contributes to the
antiapoptosis of astrocytes. After 24 h of IL-1β treatment,
CEBPD indeed responded to IL-1β stimulation and the level
of apoptosis in U373MG and primary mouse astrocytes was
not significantly different from that before treatment
(Fig. 2a, b). In contrast to astrocytes, we found decreased
CEBPD in and increased death of neuronal SH-SY5Y cells
after 24 h of IL-1β treatment (Fig. S1B). To assess if CEBPD
plays an antiapoptotic role in astrocytes, we generated
U373MG cells that stably expressed CEBPD. As shown in
Fig. 2c, the overexpression of CEBPD in U373MG cells
increased survival and reduced apoptosis after exposure to
MMS, a strong apoptosis inducer. Importantly, in Cebpd+/+
and Cebpd−/− primary astrocytes, the cells lacking CEBPD
showed increased cell death after IL-1β treatment (Fig. 2d).
These data suggest that increased CEBPD in astrocytes has a
functional role in antiapoptosis
ZNF179 Gene is a Direct Target of CEBPD
We found that the expression of ZNF179 was responsive to
IL-1β treatment in astrocytes (Fig. 3a). Furthermore, the
expression of ZNF179 paralleled that of CEBPD in astrocytes































































































Fig. 1 Astrocyte activation was decreased in AppTg/Cebpd−/− mice. a
Astrocyte numbers were decreased in the area surrounding β-amyloid
plaques in AppTg/Cebpd−/− mice. The brain tissue was subjected to
immunofluorescence with anti-GFAP and anti-β-amyloid. bQuantitative
analysis of GFAP staining in cortex and hippocampus brain sections of
AppTg and AppTg/Cebpd−/− mice using TissueQuest software. c Loss of
CEBPD promotes astrocyte death in AppTg/Cebpd−/− mice. The brain
tissue was subjected to immunofluorescence with anti-GFAP and anti-
cleaved caspase-3 (cCap3). d Quantitative analysis of GFAP and cCap3
immunofluorescent signal in whole brain sections of AppTg and AppTg/
Cebpd−/− mice using TissueQuest software. (**p<0.01, Student’s t test).
cCap3 cleaved caspase-3; GFAP glial fibrillary acidic protein
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between ZNF179 and CEBPD. A reporter assay showed that
Cebpd could activate a Znf179 promoter-driven reporter, but
the expressed Znf179 had no effect on a Cebpd promoter-
driven reporter (Fig. S2). These data suggest that CEBPD
is an upstream regulator of the ZNF179 gene in astro-
cytes. Moreover, the effect of IL-1β-induced Znf179 tran-
scription was attenuated in primary astrocyte cultures de-
rived from Cebpd−/− mice (Fig. 3b). A similar result was
found for CEBPD-related ZNF179 transcription and ex-
pression in U373MG cells (Fig. 3c). Using a serial dele-
tion reporter assay, we identified a potent CEBPD respon-
sive region in the ZNF179 promoter at −282/+72 bp
(Fig. 3d). In addition, an in vivo DNA binding assay
showed that the binding of CEBPD on the ZNF179 pro-
moter was responsive to IL-1β in U373MG cells
(Fig. 3e). These data suggest that CEBPD regulates
ZNF179 transcription by directly binding to the ZNF179
promoter region.
ZNF179 Expression in Astrocytes Contributes
to Antiapoptosis
Although a previous study suggested that ZNF179 might
contribute to the survival of neurons [12], the effect of
ZNF179 in astrocytes is unknown. ZNF179 has been sug-
gested to be a brain-specific gene [12, 19]. An immunofluo-
rescence assay showed that ZNF179 was detectable in the
GFAP-positive astrocytes of AppTg mice and was attenuated
in the astrocytes of AppTg/Cebpd−/− mice (Fig. 4a). To deter-
mine if ZNF179 plays an antiapoptotic role, we established
the stable expression of ZNF179 in human cervical HeLa
cells. After MMS or TNFα exposure, HeLa cells with
a b












































































































































Fig. 2 CEBPD promotes astrocyte survival and activation after exposure
to inflammatory cytokines. a Primary mouse astrocyte and b U373MG
cells are resistant to IL-1β-induced cell death. The dead cells were stained
with PI and were localized to the sub-G1 population using flow cytom-
etry. RT-PCR and Western blot analyses were conducted with specific
primers and the indicated antibodies using total RNA and protein lysates
harvested from IL-1β-treated cells. c CEBPD protects U373MG cells
against MMS-induced death. The MTT assay and PI staining were
conducted as indicated. d Loss of CEBPD in primary astrocyte cultures
increased cell death after IL-1β treatment. The PI staining was conducted
as indicated. (*p<0.05, **p<0.01, Student’s t test). CD CEBPD; n.s. not
significant
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ZNF179 showed a resistance to MMS- or TNFα-induced
apoptosis (Fig. S3A and S3B). A similar result was observed
in U373MG cells stably expressing ZNF179 (Fig. 4b, c). A
gain-of-function approach was used to assess if the lack of
ZNF179 or CEBPD impacts the IL-1β-induced apoptosis of
astrocytes. U373MG cells with reduced ZNF179 showed a
loss of CEBPD and increased apoptosis after IL-1β exposure
(Fig. 4d). Furthermore, the attenuation of ZNF179 decreased
the CEBPD-related antiapoptotic effect after MMS exposure
(Fig. 4e). These results suggest that ZNF179 is expressed in
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Fig. 3 CEBPD directly regulates ZNF179 transcription in U373MG
cells. a Primary mouse astrocytes (left panel) and U373MG cells (right
panel) were responsive to IL-1β treatment. RT-PCR and Western blot
analyses were conducted with specific primers and the indicated antibod-
ies using total RNA and protein lysates harvested from IL-1β-treated
cells. b The lack of Cebpd did not induce Znf179 expression in primary
astrocyte cultures. A Q-PCR assay was performed using total RNA
harvested from Cebpd+/+ and Cebpd−/− primary astrocytes. c CEBPD
participates in IL-1β-induced ZNF179 transcription. RT-PCR and West-
ern blots were performed with total RNA and protein lysates harvested
from stable U373MG cells with pMT-CEBPD expression vector (right
panel) or IL-1β-treated U373MG cells with or without attenuation of
CEBPD (left panel). d The identification of CEBPD responsive motifs on
the ZNF179 promoter region. The representation of reporter constructs
(upper panel). A reporter assay was conducted using the luciferase
activity of the ZNF179 reporter/CEBPD expression vector co-transfected
cell lysates. e CEBPD directly binds to the ZNF179 promoter in vivo. A
chromatin immunoprecipitation assay was performed with the immuno-
precipitation products at the indicated Abs from U373MG cells treated
with IL-1β. (*p<0.05, **p<0.01, ***p<0.001, Student’s t test). shCD
short hairpin CEBPD; HA/CD HA-tagged CEBPD; n.s. not significant;
IP immunoprecipitation; Abs antibodies
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The Identification of ZNF179-Regulated Genes in U373MG
Cells
We demonstrated that ZNF179 plays a functional role in
antiapoptosis. However, the ZNF179-responsive genes related
to the antiapoptotic processes in astrocytes remain unknown.
Genome-wide profiling and comparisons were conducted
using U373MG cells with and without the stable expression
of HA/ZNF179. As shown in Fig. 5a, we found that a total of
98 genes were significantly induced by ZNF179 and 339
genes were inhibited by ZNF179 in U373MG cells. Among
these ZNF179-responsive genes, four proapoptotic genes,
including RYBP [20], BIK [21], GADD45B [22] and
IGFBP3 [23, 24], were downregulated by ZNF179. RT-PCR
and Q-PCR assays confirmed the findings from the microar-
ray profile (Fig. 5b).
ZNF179 Inhibits IGFBP3 and BIK Expression by Interacting
with PLZF in Astrocytes
We next sought to determine if these ZNF179-regulated genes












































































































Fig. 4 ZNF179 attenuates the
IL-1β/MMS-induced death of
U373MG cells. a Znf179 is
highly expressed in the astrocytes
of AppTg mice when compared
with AppTg/Cebpd−/− mice.
Sagittal sections of brain cortex
were prepared from AppTg and
AppTg/Cebpd−/− mice and then
subjected to immunofluorescence
with anti-GFAP, and anti-Znf179
antibodies. b and c ZNF179
protects U373MG cells against
MMS-induced death. The MTT
assay and PI staining were
conducted as indicated. d Loss of
CEBPD or ZNF179 increased cell
death after IL-1β treatment. The
PI staining was conducted as
indicated. e The knockdown of
ZNF179 in CEBPD
overexpressing cells increased
cell death after MMS treatment.
The PI staining was conducted as
indicated (*p<0.05, **p<0.01,
***p<0.001, Student’s t test). HZ
HA-tagged ZNF179; shCD short
hairpin CEBPD; shZN short
hairpin ZNF179; GFAP glial
fibrillary acidic protein; HA/CD
HA-tagged CEBPD; shLacZ,
shβ-galactosidase
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that only the IGFBP3 and BIK transcripts out of the four
ZNF179-responsive proapoptotic genes were downregulated
in IL-1β-treated astrocytes (Fig. 6a). PLZF protein belongs to
the family of Krüppel-like zinc finger proteins. Our recent
study showed that ZNF179 can interact with PLZF in neurons
[25]. Here, a Co-immunoprecipitation assay showed that
ZNF179 also interacted with PLZF in astrocytes (Fig. 6b).
Focusing on IGFBP3 and BIK, a serial deletion of IGFBP3
and BIK promoters were cloned into a pGL3 basic vector. We
identified two putative PLZF binding motifs at −535/−543
and −452/−460 of the IGFBP3 promoter region and three
motifs at −498/−488, −425/−416, and −376/−368 of the BIK
promoter region (Fig. 6c, upper panel). Using a reporter assay,
we found that overexpression of PLZF repressed the activities
of IGFBP3 and BIK reporters containing potent PLZF binding
sites. The co-transfection of PLZF and ZNF179 expression
vectors showed an extensive effect on the repression of
IGFBP3 and BIK reporter activity (Fig. 6c, bottom panel).
Furthermore, the loss of ZNF179 reduced the PLZF-mediated
repression of IGFBP3 and BIK reporter activity after IL-1β
exposure (Fig. 6d). To verify if the IGFBP3 and BIK genes
were directly regulated via the binding of PLZF and ZNF179,
lysates of IL-1β-treated U373MG cells were subjected to a
chromatin immunoprecipitation assay. Our results show that
the binding of PLZF and ZNF179 to the IGFBP3 and BIK
promoter was responsive to IL-1β in U373MG cells (Fig. 6e).
These data suggest that PLZF is an important component of
IL-1β-induced ZNF179-mediated suppression of IGFBP3
and BIK transcription.
Discussion
In addition to AD, neuroinflammation has been suggested to
play a critical role in the pathogenesis of several neurodegen-
erative disorders, including Parkinson’s disease and
Huntington’s disease [26]. Activation of astrocytes and mi-
croglia has been associated with the pathogenesis of AD.
However, the precise mechanisms involved in this process
remain largely unclear. CEBPD is critical for the activation
of astrocytes, but not for the microglia and neurons that
surround Aβ plaques in AD (Fig. S1A) [7, 8, 11]. Under
oxidative stress or inflammation, activated astrocytes were
more resistant to apoptosis when compared with neurons
(Fig. S1A and 2A) [3]. Our previous study showed that a
significant reduction in astrocytes was observed in AppTg/
Cebpd−/− mice [11]. In this study, we demonstrated that the
loss of Cebpd promoted the death of GFAP-positive cells in
the cortex and hippocampus of AppTg mice partly through the
induction of apoptosis (Fig. 1c). Moreover, we demonstrated
that the increase of CEBPD in astrocytes reduced MMS- or
IL-1β-induced apoptosis (Fig. 2). These data suggest that
CEBPD plays an antiapoptotic role in astrocytes, especially
in a stress environment.
Elevated CEBPD expression has been mainly found in the
astrocytes of AD patients and AppTg mice [7, 8, 11]. We
determined that the activation of CEBPD in astrocytes results
in attenuation of macrophage-mediated phagocytosis of dam-
aged neurons, and also contributes tomicroglial activation and








































* ** ** **
Fig. 5 The identification of
ZNF179-regulated genes in
astrocytes. a A microarray
analysis was performed using
total RNA harvested from stable
U373MG cells with a pcDNA-
HA-ZNF179 expression vector. b
The verification of CEBPD
responsive genes in antiapoptosis.
RT-PCR and Q-PCR assays were
conducted using total RNA
harvested from HA and HZ
U373MG cells. (*p<0.05,
**p<0.01, Student’s t test).
HZ HA-tagged ZNF179
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environments, neurons are more sensitive than astrocytes
because they have lower antioxidant capabilities and are
therefore prone to excitotoxicity [27]. Our novel findings
suggest that astrocytic CEBPD plays an antiapoptotic role,
which contributes to the resistance of inflammation-induced
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the first evidence to support ZNF179’s antiapoptotic role,
particularly in astrocytes within a damaged or inflammatory
environment.
CEBPD is induced in age-associated disorders, such as
AD, atherosclerosis [28], type 2 diabetes [29], and rheumatoid
arthritis [9, 30]. These discoveries imply that CEBPD may
play a central role in inflammation-related diseases. Our pre-
vious [8, 11] and current studies indicate that the inactivation
of CEBPD in astrocytes could improve the survival of neuron
in inflammatory diseases. Small chemical drugs (<400 Da)
may cross the blood–brain barrier via lipid-mediate-free dif-
fusion [31]. Carnosic acid can penetrate the blood–brain bar-
rier and could be a useful drug for Aβ-induced neurodegen-
eration as AD [32]. We previously demonstrated that
rosmanol (molecular weight 346.41 Da), a natural carnosic
acid, derived from the herb rosemary and inotilone (molecular
weight 218.21 Da), an unusual 5-methyl-3(2H)-furanone de-
rivative, can inhibit CEBPD activation in macrophages [9].
Therefore, rosmanol and inotilone can be tested toward the
prevention or treatment of AD in the future.
Znf179 is specifically expressed in the brain and can con-
tribute to neuronal differentiation and survival [12]. Unlike
neurons, the increase of ZNF179 in astrocytes was responsive
to inflammatory cytokines (Figs. 2, 3, and S1C). Here, we
found that the transcription of ZNF179 gene is responsive to
IL-1β through the action of enhanced binding and
transactivation activity of CEBPD on its promoter region in
astrocytes. Importantly, the antiapoptotic role of ZNF179 in
astrocytes may explain why active astrocytes are resistant to
cell death in an inflammatory environment. Interestingly, the
GSK3β inhibitor, LiCl, enhanced neuron survival but caused
growth retardation in astrocytes [33]. A study showed that
CEBPD is a GSK3β substrate, and CEBPD phosphorylation
contributes to the transcriptional regulation of CEBPD-
mediated downstream target genes. Therefore, the relevance
of GSK3β-mediated phosphorylation of CEBPD in ZNF179
transcriptional activation in astrocytes requires further
investigation.
PLZF has been suggested to be a transcriptional repressor
and antiapoptotic for neurons in stroke [34]. PLZF interacts
with SMRT/N-CoR-mSin3A-HDAC-repressing complexes to
suppress gene transcription [35, 36]. Several lines of evidence
suggest that PLZF has antiapoptotic effects. For example,
PLZF can inhibit caspase 3 and caspase 7 activity in neurons
[34]; however, the specific mechanism remains unknown. In
this study, we further found that ZNF179 expression was
activated and interacted with PLZF upon IL-1β treatment to
promote antiapoptosis in astrocytes. IGFBP3 is a common
pro-apoptosis gene, and it has been shown to enhance and
attenuate the actions of IGF-I [37]. IGF-I is mediated by the
IGF-I receptor and interacts with IGFBP3 to inhibit cell
growth and induce apoptosis [24]. Previous studies showed
that IGFBP3 activates the apoptotic pathway through Bcl2
family [38]. Increased PLZF attenuated IGFBP3 transcription.
A constitutive binding of PLZF and increased binding of
ZNF179 on the IGFBP3 promoter were observed after IL-
1β treatment. However, the nuclear-cytoplasmic shuttle of
ZNF179 did not change in response to IL-1β stimulation
(Fig. S4). This observation implies that cytosolic and nuclear
ZNF179 may play distinct roles in IL-1β-treated astrocytes.
These data also suggest that IL-1β can induce nuclear
ZNF179 binding to the preexisting PLZF on IGFBP3 and
BIK promoter to suppress its transcription. Although
the transcription of the proapoptotic GADD45B and RYBP
genes is repressed by the overexpression of ZNF179, our
preliminary results show that exposure to IL-1β has no effect
on GADD45B and RYBP transcription. These data suggest
that ZNF179 can interact with other IL-1β-independent
transcription repressors or complexes to repress gene
transcription; however, this hypothesis needs to be further
investigated
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Fig. 6 ZNF179 downregulates IGFBP3 and BIK expression through
interaction with PLZF. a IGFBP3 and BIK expression was
downregulated after IL-1β treatment. The Q-PCR assay was performed
using total RNA harvested from U373MG cells. b The interaction of
ZNF179 and PLZF was revealed using immunoprecipitation analysis of
an EGFP-PLZF plasmid transiently transfected together with HA or HA-
ZNF179 plasmids. c The interaction of ZNF179 with PLZF can
downregulate IGFBP3 and BIK promoter activity. A representation of
reporter constructs are shown (upper panel). Using cell lysates, the
reporter assay was conducted by examining the luciferase activity of a
co-transfected IGFBP3 reporter or BIK reporter/ZNF179 expression
vector/PLZF expression vector. d ZNF179 reduces IGFBP3 reporter or
BIK reporter activities after IL-1β treatment in U373MG cells. Lentiviral
vectors were used to express shLacZ and shZNF179. After a 2-day
infection, these constructs were co-transfected with expression and
promoter vectors. A reporter assay was conducted using the luciferase
activity within cell lysates. e The interaction of ZNF179 with PLZF can
directly binds to the IGFBP3 and BIK promoter in vivo. A chromatin
immunoprecipitation assay was performed with the immunoprecipitation
products at the indicated Abs from U373MG cells treated with IL-
1β. (*p<0.05, **p<0.01, ***p<0.001, Student’s t test). shZN short
hairpin ZNF179; FL full length; PI promoter I; PII promoter II; shLacZ
shβ-galactosidase
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